CU20170078A7 - DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER - Google Patents

DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER

Info

Publication number
CU20170078A7
CU20170078A7 CUP2017000078A CU20170078A CU20170078A7 CU 20170078 A7 CU20170078 A7 CU 20170078A7 CU P2017000078 A CUP2017000078 A CU P2017000078A CU 20170078 A CU20170078 A CU 20170078A CU 20170078 A7 CU20170078 A7 CU 20170078A7
Authority
CU
Cuba
Prior art keywords
phenyl
inappropriate cellular
propanamide
triazolo
useful
Prior art date
Application number
CUP2017000078A
Other languages
English (en)
Inventor
Ursula Krenz
Dr Hans-Georg Lerchen
Dr Philip Lienau
Dr Ulrich Lücking
Dr Volker Schulze
Dr Gerhard Siemeister
Dr Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170078A7 publication Critical patent/CU20170078A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>Derivados sustituidos de N-(4-(2-(fenilamino)-(1,2,4)-triazolo (1,5-a) piridin-7-il)-fenil)-2-(fenil)-propanamida de fórmula (I) en calidad de profármacos de inhibidores de la quinasa Mps-1.</p> <p>ESPACIO PARA FÓRMULA</p> <p>Estos derivados son útiles para tratar enfermedades relacionadas con el crecimiento, una proliferación y/o una supervivencia celular descontrolada, con una respuesta inmune celular inapropiada o con una respuesta inflamatoria celular inapropiada, o enfermedades que están acompañadas por un crecimiento, una proliferación y/o una supervivencia celular descontrolada, por una respuesta inmune celular inapropiada o por una respuesta inflamatoria celular inapropiada, particularmente donde el crecimiento, la proliferación y/o la supervivencia celular descontrolada, la respuesta inmune celular inapropiada o la respuesta inflamatoria celular inapropiada están mediados por Mps-1</p>
CUP2017000078A 2014-12-09 2015-12-07 DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER CU20170078A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09
PCT/EP2015/078871 WO2016091825A1 (en) 2014-12-09 2015-12-07 Compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
CU20170078A7 true CU20170078A7 (es) 2017-10-05

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000078A CU20170078A7 (es) 2014-12-09 2015-12-07 DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER

Country Status (27)

Country Link
US (1) US20170342064A1 (es)
EP (1) EP3230285A1 (es)
JP (1) JP2017537116A (es)
KR (1) KR20170088872A (es)
CN (1) CN107001376A (es)
AR (1) AR102947A1 (es)
AU (1) AU2015359593A1 (es)
BR (1) BR112017012317A2 (es)
CA (1) CA2969902A1 (es)
CO (1) CO2017005741A2 (es)
CR (1) CR20170243A (es)
CU (1) CU20170078A7 (es)
DO (1) DOP2017000136A (es)
EA (1) EA201791264A1 (es)
EC (1) ECSP17036251A (es)
IL (1) IL252237A0 (es)
MA (1) MA41136A (es)
MX (1) MX2017007655A (es)
NI (1) NI201700072A (es)
PE (1) PE20170927A1 (es)
PH (1) PH12017501063A1 (es)
SG (1) SG11201704684PA (es)
TN (1) TN2017000241A1 (es)
TW (1) TW201625565A (es)
UY (1) UY36421A (es)
WO (1) WO2016091825A1 (es)
ZA (1) ZA201704589B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917467A (zh) * 2021-01-22 2023-10-20 渤健马萨诸塞州股份有限公司 用以增加重组病毒载体滴度的微管去稳定剂添加剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas

Also Published As

Publication number Publication date
TW201625565A (zh) 2016-07-16
ZA201704589B (en) 2019-02-27
PE20170927A1 (es) 2017-07-13
BR112017012317A2 (pt) 2018-04-24
NI201700072A (es) 2017-07-17
DOP2017000136A (es) 2017-08-31
MX2017007655A (es) 2017-10-11
JP2017537116A (ja) 2017-12-14
CO2017005741A2 (es) 2017-08-31
US20170342064A1 (en) 2017-11-30
PH12017501063A1 (en) 2017-12-11
IL252237A0 (en) 2017-07-31
AU2015359593A1 (en) 2017-06-08
CA2969902A1 (en) 2016-06-16
CN107001376A (zh) 2017-08-01
EA201791264A1 (ru) 2017-12-29
CR20170243A (es) 2017-07-26
MA41136A (fr) 2017-10-17
EP3230285A1 (en) 2017-10-18
ECSP17036251A (es) 2017-06-30
UY36421A (es) 2016-06-30
SG11201704684PA (en) 2017-07-28
WO2016091825A1 (en) 2016-06-16
AR102947A1 (es) 2017-04-05
KR20170088872A (ko) 2017-08-02
TN2017000241A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
HUE059624T2 (hu) N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
CU20170029A7 (es) Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
MX2021009673A (es) Moduladores de ror-gamma.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
EA201691421A1 (ru) Гетероарилы и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2017000792A1 (es) Derivados del ácido borónico
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
MX382436B (es) Derivados de quinolin-2-ona.
CO2019008110A2 (es) Activador de nrf2
MX388612B (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
CU20170078A7 (es) DERIVADOS SUSTITUIDOS DE N-(4-(2-(FENILAMINO)-(1,2,4)-TRIAZOLO (1,5-a) PIRIDIN-7-IL)-FENIL)-2-(FENIL)-PROPANAMIDA ÚTILES PARA EL TRATAMIENTO DEL CÁNCER